论文部分内容阅读
目的观察醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效。方法选取2011年9月—2016年2月南京医科大学第一附属医院收治的急性脑出血患者111例,随机分为对照组56例和观察组55例。在常规治疗基础上,对照组患者给予依拉达奉,观察组患者给予依拉达奉联合醒脑静注射液;两组患者均连续治疗14 d。比较两组患者治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、格拉斯哥昏迷量表(GCS)评分及临床疗效。结果治疗前两组患者NIHSS、GCS评分比较,差异无统计学意义(P>0.05);治疗后观察组患者NIHSS评分低于对照组,GCS评分高于对照组(P<0.05)。治疗后,两组患者NIHSS评分均低于治疗前,GCS评分均高于治疗前(P<0.05)。观察组患者临床疗效优于对照组(P<0.05)。结论醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效确切,可有效改善患者神经功能和意识状态。
Objective To observe the clinical effect of xingnaojing injection combined with edaravone in the treatment of acute cerebral hemorrhage. Methods 111 patients with acute cerebral hemorrhage admitted from the First Affiliated Hospital of Nanjing Medical University from September 2011 to February 2016 were randomly divided into control group (56 cases) and observation group (55 cases). On the basis of routine treatment, patients in the control group were treated with Eradan Bong, while those in the observation group were treated with Elada Fengxinjing Injection; both groups were treated for 14 consecutive days. The National Institutes of Health Stroke Scale (NIHSS) score, Glasgow coma scale (GCS) score, and clinical outcome were compared between the two groups before and after treatment. Results There was no significant difference in NIHSS and GCS scores between the two groups before treatment (P> 0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group, and the GCS score was higher than that of the control group (P <0.05). After treatment, NIHSS scores of both groups were lower than before treatment, GCS scores were higher than before treatment (P <0.05). The clinical efficacy of the observation group was better than that of the control group (P <0.05). Conclusion Xingnaojing injection combined with edaravone in the treatment of acute intracerebral hemorrhage has definite curative effect and can effectively improve the neurological function and consciousness of patients.